Gameto is a biotechnology company translating the impact of ovarian aging to develop solutions to improve fertility and stop the impact of menopause on female health.

Gameto's scientific work involves reconstituting ovarian development and function in vitro, elucidating the underlying growth factor and genetic networks that drive human ovarian development and oogenesis. We aim to leverage our allogeneic human cellular derivatives of our platform to therapeutic applications for assisted fertility and menopause.

• Industry

  • Biotechnology
  • Health + Tech

• Milestones

  • Lux investment: 2021

• Founders

  • Dr. Dina Radenkovic
  • Martin Varsavsky

  LUX Partners

  • Deena Shakir

• Latest Tweets

  • An exciting study out last month comparing human and mice oocytes/embryos revealed aspects of distinct and shared t… https://t.co/B5XPrW0HNT@GametoGen - 19h
  • Last month, @DinaRadenkovic led the panel Future of Tech x Bio: Investing & Company Building with @rtnarch… https://t.co/nlLp8lUpo5@GametoGen - 02:59 PM Oct 3rd
  • We are excited for @DinaRadenkovic to speak with @jenngarrison today at the Longevity - Coming of Age Conference! https://t.co/aEqyWEBTmK@GametoGen - 01:03 PM Sep 29th